phenoxodiol + paclitaxel

Phenoxodiol + paclitaxel is an experimental **combination therapy** evaluated mainly in the treatment of chemo-resistant or refractory cancers, chiefly ovarian cancer. **Phenoxodiol** is a synthetic isoflavene developed as a chemosensitizer, meaning it may enhance the cancer cell-killing effects of other anticancer agents, including paclitaxel. Phenoxodiol acts by modulating apoptotic pathways in tumor cells—disrupting FLICE-inhibitory protein (FLIP), reducing expression of the anti-apoptotic XIAP protein, promoting caspase activation, and inhibiting plasma membrane electron transport (PMET); it is also believed to reduce pro-survival signals mediated by sphingosine-1-phosphate (S-1-P)[2][5]. **Paclitaxel** is a well-established microtubule-stabilizing **antineoplastic agent**, causing cell cycle arrest and apoptosis in dividing cells. The combination has specifically been tested in platinum/taxane-resistant ovarian cancer, where phenoxodiol is intended to *sensitize* cancer cells to paclitaxel, potentially overcoming drug resistance and improving efficacy[1][4][5]. Clinical studies suggest the combination is well-tolerated[1]. This combination has also been explored in other cancers such as prostate cancer, though evidence of synergy is disease- and context-specific[3].